EU Pharma Supply Chain Diversification: Why India Is the Biggest Beneficiary

The COVID-19 pandemic exposed a critical EU pharmaceutical supply chain dependency — approximately 80% of APIs used by EU manufacturers were sourced from a small number of countries, with China dominating many key generic molecule supply chains. EU governments have responded with explicit policy interventions to diversify.

EU policy interventions creating India API opportunity: (1) HERA (European Health Emergency Preparedness and Response Authority) — EUR 6B fund supporting pharmaceutical supply chain diversification; (2) EU Critical Medicines Act — identifying critical medicines requiring supply chain resilience measures; (3) EU member state strategic stockpiling — requiring manufacturers to maintain 4-6 months of API stock, incentivising multi-supplier sourcing; (4) EU procurement preference for pharmaceutical products from diversified supply chains.

Why India specifically benefits: India has pre-existing WHO-GMP and EU-GMP certified capacity across most key generic API categories. India' API production cost advantage versus EU domestic: 40-60%. India' relationship with EU regulatory authorities has systematically improved since 2019. India has CEP coverage from EDQM for most key generic molecule APIs.

What Indian API manufacturers must do to capture this opportunity: (1) Obtain EU GMP certificate — the non-negotiable entry requirement; (2) Apply for EDQM CEP for key APIs — enables easy referencing by any EU marketing authorisation holder; (3) Attend CPhI Europe (Frankfurt) — the primary forum where EU buyers announce new sourcing requirements; (4) Engage PHARMEXCIL' EU supply chain diversification programme; (5) Contact AJG for mandate-facilitated connections to EU pharma companies actively seeking Indian API supply.